放化疗联合IL-2/LAK治疗局部晚期NSCLC术后残余的临床研究  

Radiochemotherapy combined with IL-2/LAK therapy for locally advanced NSCLC with postoperative residual cancer

作　　者：朱江 陈桂明 

机构地区：[1]荆门市第二人民医院肿瘤内一科,湖北荆门448000

出　　处：《实用肿瘤杂志》2015年第3期252-255,共4页Journal of Practical Oncology

摘　　要：目的探讨在局部晚期非小细胞肺癌术后残余患者中应用放化疗联合白细胞介素-2(interleukin-2,IL-2)/淋巴因子激活的杀伤细胞(lymphokine activated killer,LAK)生物治疗法的临床疗效。方法对44例局部晚期非小细胞肺癌术后残余患者,按照随机数字表法,分为对照组22例与观察组22例。对照组给予单纯放化疗,观察组在放化疗基础上联合采用IL-2/LAK生物治疗法,并对两组的治疗效果、治疗后生存率及不良反应进行比较。结果观察组患者的治疗有效率为81.8%,高于对照组的50.0%,差异具有统计学意义(P<0.05)。观察组患者1、2、3年的生存率分别为81.8%、72.7%、50.0%,均高于对照组(50.0%、31.8%、22.7%),差异具有统计学意义(P<0.05)。两组患者在放化疗期间出现的白细胞减少、恶心/呕吐、血红蛋白降低及放射性肺炎等不良反应严重程度比较,差异有统计学意义(均P<0.05)。结论在局部晚期非小细胞肺癌术后残余患者中应用放化疗联合IL-2/LAK生物治疗法,可提高治疗效果与远期生存率,治疗安全性较高。Objective To evaluate the efficacy of ratiochemotherapy combined with interleukin-2 / lymphokine activated killer（ IL-2 / LAK） for locally advanced non-small-cell lung cancer（ NSCLC） patients with postoperative residual cancer. Methods Forty-four locally advanced NSCLC patients with postoperative residual cancer were randomly assigned into two groups. Twenty-two patients received radiochemotherapy with IL-2 / LAK therapy（ study group） and 22 received radiochemotherapy alone（ control group）. Efficacy、survival rates and adverse reactions were documented. Results The effective rate of study group was significantly higher than that of control group（ 81. 8% vs 50. 0%,P 0. 05）. The 1-,2-,3-year survival rates of study group were significantly higher than those of control group（ 81. 8% vs 50. 0%,72. 7% vs31. 8% and 50. 0% vs 22. 7%,respectively,P 0. 05）. The severity of adverse reactions,including leukopenia,nausea /vomiting,lower hemoglobin and radioactive pneumonia,in study group was significantly lower than that in control group（ all P 0. 05）. Conclusion The combination of radiochemotherapy with IL-2 / LAK biological therapy can significantly improve the therapeutic efficacy and long-term survival for locally advanced NSCLC patients with postoperative residual cancer.

关 键 词：肺肿瘤/外科学 手术后期间 癌 非小细胞肺/放射疗法 癌 非小细胞肺/药物疗法 白细胞介素2/治疗应用 杀伤细胞 淋巴因子激活 抗肿瘤联合化疗方案/治疗应用 综合疗法 存活率 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤] R730.56[医药卫生—临床医学]